v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Cash flows from operating activities:              
Net loss $ (5,092,000) $ 2,707,000 $ (6,111,000) $ (921,000) $ (45,050,000) $ (12,358,000)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Stock-based compensation         1,323,000 1,498,000  
Depreciation and amortization 11,000   18,000   59,000 82,000  
Amortization of debt discounts         1,260,000 779,000  
Increase (decrease) in fair value of warrant liability (6,000)   (284,000)   29,120,000 (6,134,000)  
Loss on extinguishment of convertible note payable           837,000  
Changes in operating assets and liabilities:              
Accounts receivable         117,000 (160,000)  
Inventories         877,000 3,901,000  
Prepaid expenses and other current assets         (215,000) (149,000)  
Other assets         72,000 67,000  
Accounts payable         (842,000) (84,000)  
Accrued liabilities         59,000 (319,000)  
Other liabilities         (56,000) (61,000)  
Net cash used in operating activities         (13,276,000) (12,101,000)  
Cash flows from investing activities:              
Issuance of notes receivable         (323,000)    
Purchases of property and equipment         (28,000) (50,000)  
Net cash used in investing activities         (351,000) (50,000)  
Cash flows from financing activities:              
Proceeds from issuance of common stock, prefunded warrants and warrants, net of issuance costs         19,558,000 7,995,000  
Proceed from issuance of common stock in connection with warrant exercise         3,198,000 2,545,000  
Proceed from exercises of Series B preferred stock warrants         714,000    
Proceeds from issuance of short-term loan, net of issuance costs         600,000 598,000  
Repurchase of Series B preferred stock warrants         (6,266,000)    
Repayment of short-term loan         (667,000)    
Repayment of convertible note payable, net of issuance costs           (1,657,000)  
Repayment of finance lease           (15,000)  
Net cash provided by financing activities         17,137,000 9,466,000  
Net decrease in cash and cash equivalents         3,510,000 (2,685,000)  
Cash and cash equivalents as of beginning of period   $ 411,000   $ 2,897,000 411,000 2,897,000 $ 2,897,000
Cash and cash equivalents as of end of period 3,921,000   $ 212,000   3,921,000 212,000 $ 411,000
Supplemental disclosure of cash flow information:              
Cash paid for interest         276,000 20,000  
Cash paid for income taxes           2,000  
Noncash Investing and Financing Activities:              
Conversion of liability warrants to equity warrants         41,851,000    
Issuance of warrant liability in connection with financing         8,701,000    
Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock         5,842,000    
Repurchase of Series B preferred stock warrants         824,000    
Issuance of common stock to vendors $ 240,000       600,000    
Cashless exercise of warrants         587,000 8,191,000  
Warrant exercise in connection with loan settlement         333,000    
Issuance of common stock in connection with Series B preferred stock         325,000    
Unpaid financings issuance costs         $ 269,000    
Issuance of warrant liability in connection with February 2023 offering           5,601,000  
Issuance of common stock in connection with convertible promissory note           708,000  
Record Right-of-Use Assets obtained in exchange for modified operating lease liabilities           554,000  
Deferred offering costs reclassed from prepaid expenses           97,000  
Accrual of legal fees for the short-term loan           $ 10,000  

Source

PDF HTML 10-Q Filing
ZIP XLS HTML XBRL